{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:18:27Z","timestamp":1771503507191,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,11,14]],"date-time":"2007-11-14T00:00:00Z","timestamp":1194998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Osteolytic bone disease (OBD) in multiple myeloma (MM) is caused by interactions between MM cells and the bone marrow microenvironment and is characterized by increased osteoclastic bone resorption and decreased osteoblastic bone formation. Recently, the role of osteoblast inhibition has come into focus, especially the possible role of overexpression of <jats:italic>DKK1<\/jats:italic>, an inhibitor of the Wnt signalling pathway. Further, <jats:italic>CKS2<\/jats:italic>, <jats:italic>PSME2<\/jats:italic> and <jats:italic>DHFR<\/jats:italic> have also been reported as candidate genes for OBD. We studied the gene expression by quantitative reverse transcription polymerase chain reaction of <jats:italic>TNFSF11 (RANKL)<\/jats:italic>, <jats:italic>TNFSF11A (RANK)<\/jats:italic>, <jats:italic>TNFRSF11B (OPG)<\/jats:italic>, <jats:italic>CCL3<\/jats:italic> (<jats:italic>MIP1A)<\/jats:italic>, <jats:italic>CCL4 (MIP1B)<\/jats:italic>, <jats:italic>PTHR1 (PTHrp)<\/jats:italic>, <jats:italic>DKK1<\/jats:italic>, <jats:italic>CKS2<\/jats:italic>, <jats:italic>PSME2<\/jats:italic> and <jats:italic>DHFR<\/jats:italic> in purified, immunophenotypic FACS\u2010sorted plasma cells from 171 newly diagnosed MM patients, 20 patients with monoclonal gammopathy of undetermined significance and 12 controls. The gene expressions of the analysed genes were correlated with radiographically assessed OBD. Only overexpression of <jats:italic>DKK1<\/jats:italic> was correlated to the degree of OBD. Myeloma cells did not express <jats:italic>TNFSF11A<\/jats:italic>, <jats:italic>TNFSF11,<\/jats:italic> or <jats:italic>TNFRSF11B<\/jats:italic>, and very rarely expressed <jats:italic>CCL3<\/jats:italic> and <jats:italic>PTHR11<\/jats:italic>. <jats:italic>CCL4<\/jats:italic>, <jats:italic>CKS2<\/jats:italic>, <jats:italic>PSME2<\/jats:italic> and <jats:italic>DHFR<\/jats:italic> were variably expressed, but the expression of these genes showed no correlation with OBD. In contrast, loss of <jats:italic>PSME2<\/jats:italic> expression in MM plasma cells was significantly correlated with OBD.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2007.06871.x","type":"journal-article","created":{"date-parts":[[2007,11,17]],"date-time":"2007-11-17T06:55:52Z","timestamp":1195282552000},"page":"25-35","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of <i>DKK1<\/i> correlates with clinical bone involvement at diagnosis"],"prefix":"10.1111","volume":"140","author":[{"given":"Jacob","family":"Haaber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene Meldgaard","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inger Marie","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Lodahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gitte Birk","family":"Kerndrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,11,14]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.6.2195"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/36593"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.12.1909"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/17.8.2919"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.671"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3534"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06491.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-6-59"},{"key":"e_1_2_5_10_1","first-page":"5438","article-title":"Receptor activator of nuclear factor\u2010kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia A.N.","year":"2003","journal-title":"Cancer Research"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3527"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1121"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2006.11.015"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3349"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04864.x"},{"key":"e_1_2_5_16_1","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider U.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/74999"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-979080"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.7.3540"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2002.01314.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2001-12920"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057995"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3905"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.201394498"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5447.2162"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8 <1564::AID-CNCR6>3.0.CO;2-K"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01770.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04577.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2269"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0148"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.02.003"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1084149"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1190"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0380"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500175049"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(01)00340-4"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04040.x"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1590191"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.40.25190"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-047712"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.7.3597"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH702>3.0.CO;2-#"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2007.06871.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2007.06871.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T21:46:23Z","timestamp":1695937583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2007.06871.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,14]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1365-2141.2007.06871.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06871.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,14]]},"assertion":[{"value":"2007-11-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}